KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Short-term Investments (2018 - 2023)

Esperion Therapeutics (ESPR) has disclosed Short-term Investments for 6 consecutive years, with $17.4 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Short-term Investments fell 74.42% year-over-year to $17.4 million, compared with a TTM value of $17.4 million through Mar 2023, down 74.42%, and an annual FY2022 reading of $42.1 million, down 16.56% over the prior year.
  • Short-term Investments was $17.4 million for Q1 2023 at Esperion Therapeutics, down from $42.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $68.1 million in Q1 2022 and bottomed at $2.2 million in Q2 2020.
  • Average Short-term Investments over 5 years is $35.7 million, with a median of $33.3 million recorded in 2019.
  • The sharpest move saw Short-term Investments crashed 91.64% in 2020, then dropped 16.56% in 2022.
  • Year by year, Short-term Investments stood at $34.7 million in 2019, then crashed by 93.52% to $2.2 million in 2020, then skyrocketed by 2144.82% to $50.4 million in 2021, then decreased by 16.56% to $42.1 million in 2022, then plummeted by 58.59% to $17.4 million in 2023.
  • Business Quant data shows Short-term Investments for ESPR at $17.4 million in Q1 2023, $42.1 million in Q4 2022, and $29.9 million in Q3 2022.